Skip to main content
SpringerLink
Log in

Management of Residual Tumor in Testicular Cancer

  • Reference work entry
  • First Online:
Urologic Oncology

  • 719 Accesses

Abstract

Testicular cancer is a rare tumor but represents the most common solid tumor in patients between 20 and 30 years of age. After introduction of a Cisplatin based chemotherapy sceme in the late eighties oft he last century there was a revolutionary result with now curable patients. Nevertheless surgery still has a major impact in the multimodal treatment of patients with testicular cancer. Due to the high negative predictive value of FDG-PET in residul tumors of patients with seminoma these patients can often be followed. Compared to this in NSGCC surgery needs to be performed frequently as predictive markers with regard to the histologic specimen in the residual tumor still lack behind. Although morbidity is tried to be reduce by minimalizing the extend of resection fileds, aggressive treatment is needed in advanced cases and salvage situation with significantly increased complication rates. These points are highlighted in the following chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 599.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 899.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bachner M, Loriot Y, Gross-Goupil M, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol. 2012;23:59–64.

    Article  CAS  Google Scholar 

  • Beck SD, Lalka SG. Long-term results after inferior vena cava resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer. J Vasc Surg. 1998;28:808–14.

    Article  CAS  Google Scholar 

  • Beck SD, Foster RS, Bihrle R, Koch MO, Wahle GR, Donohue JP. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2001;165:1517–20.

    Article  CAS  Google Scholar 

  • Berglund R, Lyden S, Tsai E, et al. Nonseminomatous germ cell tumor after chemotherapy with residual mass invading the spine. Eur Urol. 2006;50:372–4.

    Article  Google Scholar 

  • Besse B, Grunenwald D, Flechon A, et al. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg. 2009;137:448–52.

    Article  Google Scholar 

  • Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ cell cancer. Ann Oncol. 2013;24:878–88.

    Article  CAS  Google Scholar 

  • Capitanio U, Jeldres C, Perrotte P, et al. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. Urology. 2009;74(2):373–7.

    Article  Google Scholar 

  • Collins C, Eckert H. Seminoma of the testis with bone involvement: a report of three cases. Clin Radiol. 1985;36:467–8.

    Article  Google Scholar 

  • De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update from the multicenter SEMPET trial. J Clin Oncol. 2004;22:1034–9.

    Article  Google Scholar 

  • Decoene J, Winter C, Albers P. False positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma. Urol Oncol. 2015;33:15–21.

    Article  Google Scholar 

  • Ehrlich Y, Bramas M, Beck S, et al. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ-cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed for complete remission? J Clin Oncol. 2010;28:531–6.

    Article  CAS  Google Scholar 

  • Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy results from an international study. J Clin Oncol. 2001;19:2647–57.

    Article  CAS  Google Scholar 

  • Fizazi K, Oldenburg J, Dunant A, et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol. 2008;19(2):259–64.

    Article  CAS  Google Scholar 

  • Fléchon A, Tavernier E, Boyle H, et al. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int. 2010;106(6):779–85.

    Article  Google Scholar 

  • Fossa S, Borge L, Aass N, Johannessen N, Stenwig A, Kaalhus O. The treatment of advanced metastastic seminoma: experience in 55 cases. J Clin Oncol. 1987;5:1071–7.

    Article  CAS  Google Scholar 

  • Hahn T, Jacobson L, Einhorn L, et al. Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol. 1999;6:640–4.

    Article  CAS  Google Scholar 

  • Heidenreich A, Pfister D, Witthuhn R, et al. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol. 2009;55(1):217–24.

    Article  Google Scholar 

  • Herr H, Sheinfeld J, Heide S, Heelan R, Bajorin D, Mencel P, Bosl G, Motzer R. Surgery for a post-chemotherapy residual mass in seminoma. J Urol. 1997;157:860–2.

    Article  CAS  Google Scholar 

  • Hitchins R, Philip P, Wignall B, et al. Bone disease in testicular and extragonadal germ cell tumours. Br J Cancer. 1988;58:793–6.

    Article  CAS  Google Scholar 

  • Iida K, Naiki T, Kawai N, et al. Metastasectomy as optimal treatment for late relapsing solitary brain metastasis from testicular germ cell tumor: a case report. BMC Res Notes. 2014;7:865.

    Article  Google Scholar 

  • Jacobsen N, Beck S, Jacobsen L, et al. Is retroperitoneal history predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection. J Urol. 2010;184:949–53.

    Article  Google Scholar 

  • Johnston P, Beck S, Cheng L, et al. Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2013;190:874–7.

    Article  Google Scholar 

  • Kollmannsberger C, Daneshmand S, So A, et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol. 2009;28:537–42.

    Article  Google Scholar 

  • Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European germ cell Cancer consensus group (EGCCCG): part I. Eur Urol. 2008;53(3):478–96.

    Article  Google Scholar 

  • Moshrafa A, Foster R, Leibovich B, Bihrle R, Johnson C, Donohue J. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol. 2003;169(6):2126–8.

    Article  Google Scholar 

  • Nash PA, Leibovitch I, Foster RS, et al. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes. J Urol. 1998;159:707–10.

    Article  CAS  Google Scholar 

  • Oechsle K, Bokemeyer C. Treatment of brain metastases from germ cell tumors. Hematol Oncol Clin North Am. 2011;25(3):605–13.

    Article  Google Scholar 

  • Oldenburg J, Fossa S, Nuver J, et al. Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi125–32.

    Article  Google Scholar 

  • Paffenholz P, Pfister D, Heidenreich A. Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours. Urologe A. 2016;55(5):632–40.

    Article  CAS  Google Scholar 

  • Pfister D, Porres D, Matveev V, et al. Reduced morbidity in resection of residual tumors after chemotherapy for seminoma. Urologe A. 2015;54:1402–6.

    Article  CAS  Google Scholar 

  • Puc H, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the memorial Sloan Kettering cancer center. J Clin Oncol. 1996;14:454–60.

    Article  CAS  Google Scholar 

  • Rivoire M, Elias D, De Cian F, et al. Multimodality treatment of patients with liver metastases from germ cell tumours. Cancer. 2001;92:578–87.

    Article  CAS  Google Scholar 

  • Stephenson AJ, Tal R, Sheinfeld J. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. J Urol. 2006;176:1996–9.

    Article  Google Scholar 

  • Uygun K, Karagol H, Kocak Z, et al. Isolated bone metastasis in testicular germ cell tumors: a case report and review of the literature. Onkologie. 2006;29:93–5.

    PubMed  Google Scholar 

  • Vallier C, Savoie PH, Delpero JR, et al. External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer. World J Urol. 2014;32(6):1573–8.

    Article  CAS  Google Scholar 

  • Winter C, Pfister D, Busch J, et al. Residual tumour size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumour resection: a multicenter analysis of the German testicular Cancer study group. Eur Urol. 2012;61:403–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Uro-Oncology and Robot Assisted Surgery, University Hospital of Cologne, Köln, Germany

    David Pfister

  2. Department of Urology, Urologic Oncology, Robot-assisted and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany

    Axel Heidenreich

Authors
  1. David Pfister
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Axel Heidenreich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Axel Heidenreich .

Editor information

Editors and Affiliations

  1. Department of Urology, University Hospital Schleswig-Holstein Campus Lübeck, Lübeck, Germany

    Axel S. Merseburger

  2. Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Regensburg, Germany

    Maximilian Burger

Section Editor information

  1. Universitätsklinikum Rostock , Urologische Klinik und Poliklinik, Rostock, Germany

    Chris Protzel

  2. Division of Oncological Urology, Department of Urology, University of Köln, Köln, Germany

    Axel Heidenreich

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Pfister, D., Heidenreich, A. (2019). Management of Residual Tumor in Testicular Cancer. In: Merseburger, A., Burger, M. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42623-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42623-5_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42622-8

  • Online ISBN: 978-3-319-42623-5

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation